December 23, 2024

ACC Issues New Post-Stroke Monitoring Guidelines

The American College of Cardiology releases a consensus document providing specific guidance for cardiac monitoring after stroke, outlining distinct approaches and recommendations based on stroke etiology.

Conexiant

December 20, 2024

Riluzole Shows Promise in Reversing Cognitive Decline from Radiation Therapy

Boosting brain-derived neurotrophic factor (BDNF) with riluzole may mitigate cognitive dysfunction from radiation therapy.

Conexiant

December 20, 2024

Long COVID Shows Five Distinct Patterns: Study

In the 2024 update, the NIH's RECOVER Initiative identified five distinct symptom patterns and new diagnostic thresholds for long COVID.

Conexiant

December 17, 2024

AHA Updates Stroke Palliative Care Guidelines

Updated statement promotes integrated palliative care for all stroke patients.

Conexiant

December 16, 2024

Migraine Medicine May Help Gut Disorders

A genetic analysis published in Neurology Genetics revealed significant shared genetic connections between migraine and various gastrointestinal disorders, suggesting avenues for targeted treatment through the CGRP pathway.

Conexiant

December 12, 2024

Brief, Vigorous Activity May Lower CV Risk in Women: Study Findings

A recent study shows that even 3.4 minutes of vigorous intermittent lifestyle physical activity per day could significantly reduce cardiovascular risk, particularly in non-exercising women.

Conexiant

December 12, 2024

New Evidence Supports Emergency Stroke Intervention

Meta-analysis of nearly 1,000 stroke patients found endovascular therapy doubled odds of functional independence and reduced mortality in vertebrobasilar occlusion, despite increased hemorrhage risk—mirroring benefits seen in anterior circulation strokes.

Conexiant

December 12, 2024

Comparing Ticagrelor and Prasugrel in ACS

In a 17,642-patient cohort study validating ISAR-REACT5's findings, prasugrel showed particular benefit in STEMI patients, with a striking 38% relative risk reduction in adverse events compared to ticagrelor, while maintaining similar bleeding risks.

Conexiant

December 11, 2024

ALS Drug Misses Trial Goals

A mid-stage trial for an experimental drug in ALS patients did not meet its main goal, with patients showing more gastrointestinal upset compared to a placebo, and differing death rates between groups. Results will be presented next year, and a long-term extension study will continue.

Reuters